AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01501903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: FNA in a single plane
Study NCT01501903 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fanning
Description: FNA in multiple planes
Study NCT04818775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Tourniquet
Description: Pneumatic Tourniquet
Study NCT02512458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study NCT02441647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KL029 Intimate Lubricant Gel
Study NCT00878865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 1 mg tablet one oral dose
Study NCT00878865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: 1 mg tablet
Study NCT01647178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TORQ assisted sternal closure
Study NCT01647178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure
Study NCT02382302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine system
Description: The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
Study NCT02807259 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-level intervention
Description: At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
Study NCT01464970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIE Artery Unclamped, Vein Clamped
Description: Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
Study NCT01464970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIE Artery clamped, Vein unclamped
Description: Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
Study NCT02807259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Description: At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
Study NCT00714818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
Study NCT00714818 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
Study NCT02332707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
Study NCT04487080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Participants will receive amivantamab intravenously.
Study NCT04487080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Participants will receive osimertinib capsules orally.
Study NCT04487080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive lazertinib tablets orally.
Study NCT04487080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally.
Study NCT04487080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo orally.
Study NCT02719223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICaS
Description: The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
Study NCT02608632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation guided by HFS
Study NCT02608632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation as standard procedure
Study NCT02332707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
Study NCT06365762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDTA Ophthalmic Solution 2.6%
Study NCT06365762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDTA Ophthalmic Solution 1.3%
Study NCT06365762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (Placebo)
Study NCT03935568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Description: 3 cohorts receiving a single oral dose of PU-AD at one time.
Study NCT03935568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 cohorts receiving a single oral dose of Placebo at one time
Study NCT03935568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 cohorts receiving multiple oral dose of Placebo at one time
Study NCT03935568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Description: 2 cohorts receiving multiple oral dose of PU-AD at one time
Study NCT02828670 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Study NCT02332707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One EBR 50 mg tablet (Part A), taken q.d. by mouth.
Study NCT04349592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
Study NCT02828670 — intervention group
Intervention type: PROCEDURE
Intervention: spleen sample
Study NCT03011944 — intervention group
Intervention type: OTHER
Intervention: Quality Improvement Program
Description: Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
Study NCT02224196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual ventilation
Description: Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
Study NCT02224196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure-controlled ventilation
Description: Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
Study NCT03035487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided prostate exam using SOC ultrasound system
Study NCT03035487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mpMRI guided prostate examination using PI-RADS v2
Description: mpMRI guided prostate examination using standard of care MRI system
Study NCT03035487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution micro-ultrasound guided prostate biopsy
Study NCT01656356 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avian Flu Vaccine
Study NCT01656356 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04732013 — intervention group
Intervention type: OTHER
Intervention: No clinical intervention is planned; study is observational
Description: No intervention
Study NCT03359018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
Study NCT03359018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
Study NCT02324634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTrac Rehab dual channel device
Description: ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
Study NCT03908489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vital pulpotomy primary molars using garlic oil
Description: vital pulpotomy using garlic oil
Study NCT03908489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulpotomy using mta
Description: mta vital pulpotomy
Study NCT02382484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A dual chamber pacing system (BackBeat Medical)
Description: For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
Study NCT02105753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1210nm Diode Laser treatments
Study NCT04668027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: impulse oscillation（IOS）
Description: The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
Study NCT04668027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchial provocation test(BPT)
Description: Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
Study NCT04668027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchial dilation test(BDT)
Description: The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
Study NCT01588756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AcSDKP-NH2 inuline
Description: Once intravenous administration of 100 µg or less
Study NCT01588756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AcSDKP-NH2 Cr-EDTA
Description: Once intravenous administration of 100 µg or less
Study NCT00732836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Abraxane
Description: Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
Study NCT05421000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: Wide awake local anesthesia without tourniquet for distal radius fracture surgery
Study NCT00732836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Catheter
Description: On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
Study NCT00732836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Abraxane
Description: Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
Study NCT01827683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric oxygen
Description: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
Study NCT01827683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
Study NCT04094415 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
Study NCT04241978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PtDA)
Description: Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
Study NCT05421000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional anesthesia and tourniquet
Description: Locoregional anesthesia and tourniquet for distal radius fracture surgery
Study NCT01431183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed influenza vaccination reminder notice
Description: Influenza vaccination reminder sent by postal mail
Study NCT02088385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray
Study NCT02088385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Conventional Technique
Study NCT02266173 — intervention group
Intervention type: DRUG
Intervention: Pertuzumab
Description: Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
Study NCT02594488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Reveal LINQ implantable cardiac monitor
Description: The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
Study NCT02953808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
Study NCT02953808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
Study NCT02953808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
Study NCT00686556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
Study NCT02332707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
Study NCT00686556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Beginning on Day -3 pre-transplant maintaining a level of >200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
Study NCT04241978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure with general information about osteoarthritis
Description: Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
Study NCT04349592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
Study NCT04349592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Study NCT00686556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
Study NCT01698307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment Algorithm
Description: The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.